FierceBiotech1h
Cell death biotech Kojin winds down, citing 4 funding challenges
Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...
FierceBiotech3h
Volta Medical’s afib AI shows gains in cardiac ablation study
Volta Medical put forward new data showing its artificial intelligence-guided ablation procedures were able to improve ...
FierceBiotech5h
Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
FierceBiotech5h
Boston biotech Bambusa banks $90M for next-gen bispecifics
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...
FierceBiotech6h
Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
FierceBiotech7h
Chutes & Ladders—Neumora overhauls C-suite after phase 3 flop
After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.
FierceBiotech8h
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
FierceBiotech10h
Otsuka breaks up with cancer candidates on strategic grounds
Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...